AstraZeneca PLC (AZN)vsUroGen Pharma Ltd (URGN)
AZN
AstraZeneca PLC
$166.15
-1.17%
HEALTHCARE · Cap: $257.57B
URGN
UroGen Pharma Ltd
$40.45
-1.10%
HEALTHCARE · Cap: $2.09B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 32415% more annual revenue ($61.37B vs $188.73M). AZN leads profitability with a 17.0% profit margin vs -51.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
URGN
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$166.15
$29.66 discount
Intrinsic value data unavailable for URGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 199.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Operating margin of 0.1%
Weak financial health signals
ROE of -1481.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 199.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Operating Margin, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while URGN is a hypergrowth play — different risk/reward profiles.
URGN carries more volatility with a beta of 1.58 — expect wider price swings.
URGN is growing revenue faster at 199.2% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 31/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?